Form 8-K EAGLE PHARMACEUTICALS, For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 9c
November 11, 2015 7:04 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of ($0.65), $0.09 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $5.07 million.
"Eagle has accomplished a great deal already this year, and we remain focused on achieving our goals in the particularly exciting and important final weeks ahead, said Scott Tarriff, President and Chief... More
